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in Observational Studies of Comparative EffectivenessTo the Editor: There has been growing interest in the use of the
transradial approach for percutaneous coronary intervention (PCI),
supported by randomized clinical trials involving experienced
transradial operators (1,2). However, the assessment of transradial
PCI in routine practice has necessarily relied on observational
comparisons (3), which may be susceptible to confounding even
with modern statistical methods. In any observational study, there
is always the possibility that unmeasured confounders bias the
intended comparison regardless of the statistical approach used,
including the use of advanced multivariable modeling or propensity
score methods. Also, observational methods are limited in their
inability to demonstrate causality.
Recently, the use of “falsiﬁcation endpoints” has been highlighted
as an underutilized method to assess for residual confounding in
observational studies (4). A “falsiﬁcation hypothesis” is a claim,
distinct from the main hypothesis being tested, that researchers
believe is highly unlikely to be causally related to the intervention
under study, similar to a “negative” control experiment in a laboratory.
Most observational studies, including those focused on this clinical
question (3), have not reported falsiﬁcation endpoints. Despite the
common parlance of the word “falsiﬁcation,” the term “falsiﬁcation
endpoints” or “falsiﬁcation hypothesis” does not imply datas With Transradial Versus Transfemoral PCI
es used on our study sample, there was a statistically s
ary intervention (PCI). This association, between our tre
at there is likely residual confounding when testing the m
tigation in ST-Elevation Acute Coronary Syndrome) rando
ggesting an unbiased comparison between the 2 treatmfalsiﬁcation or attempts on the part of the investigators to mislead the
reader. Rather, these endpoints are intended to test, within a single
study, whether signiﬁcant associations between a treatment and
outcome are susceptible to residual confounding.
We sought to compare outcomes for transradial and trans-
femoral PCI using modern statistical adjustment methods and
utilizing a falsiﬁcation endpoint. Our primary hypothesis was that
transradial PCI reduces access site bleeding compared to trans-
femoral PCI in routine clinical practice. However, because
transradial PCI would not be expected to differentially inﬂuence
bleeding apart from at the arterial access site, nonaccess site
bleeding was pre-speciﬁed as the falsiﬁcation endpoint.
Data were obtained from 5 Massachusetts hospitals from 2008 to
2011. De-identiﬁed, patient-level data were extracted using
National Cardiovascular Data Registry (NCDR) CathPCI forms in
patients undergoing PCI without mechanical circulatory support.
The dataset contained clinical and procedural elements and follow-
up for in-hospital complications. Bleeding endpoints were deﬁned
as access versus nonaccess site.
Estimates of the impact of transradial versus transfemoral PCI
were determined using 3 methodologies. In method 1, we gener-
ated standard logistic regression models adjusting for baselineigniﬁcant reduction in nonaccess site bleeding with transradial compared with
atment of interest, transradial PCI, and the pre-speciﬁed falsiﬁcation endpoint, non-
ain hypothesis. Bleeding outcomes are also presented from the RIFLE STEACS (Radial
mized trial (2). With randomization, there was no association between transradial PCI
ent strategies, as would be expected. CI ¼ conﬁdence interval; IPTW ¼ inverse
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(5). In method 2, we performed 1:1 matching of transradial and
transfemoral PCI patients based on propensity score accounting for
19 demographic, clinical, and procedural covariates including
anticoagulation strategy. In method 3, we performed adjustment
based on inverse probability treatment weights (IPTW) generated
from the propensity score model. Analyses were performed using
STATA version 11.2 (College Station, Texas).
A total of 17,509 patients underwent PCI, with 17.8%
of procedures performed via the transradial approach. A total of
240 (1.4%) patients had either access site bleeding (102 events) or
nonaccess site bleeding (144 events). Although there were statis-
tically signiﬁcant differences in 15 of 17 baseline characteristics
examined, patients undergoing transfemoral and transradial PCI
were balanced on all characteristics after using propensity score
methods (standardized differences <10% for all variables).
The results of the 3 different analyses are presented in Figure 1.
Statistically signiﬁcant reductions in access site bleeding were seen
with transradial PCI using all 3 methodologies. However, statis-
tically signiﬁcant reductions in nonaccess site bleeding were also
seen with transradial PCI with all 3 methodologies, suggesting
residual confounding.
In these analyses, we identiﬁed a relationship between transradial
PCI and nonaccess site bleeding that was not identiﬁed in
randomized clinical trials and that is most likely due to the inability
of our methods to fully adjust for unmeasured patient differences.
While it would be possible to adjust the results of the primary
hypothesis based on the magnitude of confounding of the falsiﬁca-
tion endpoint, we would not recommend this approach until the
validity of such methods has been further explored. These data
highlight the dangers of assuming that modern statistical methods
alone fully adjust for confounding in nonrandomized data. In
observational comparisons such as the comparison of transradial and
transfemoral PCI in which differences in unmeasured patient
characteristics are likely to be signiﬁcant based on treatment selec-
tion, the use of falsiﬁcation endpoints may be useful when available.Neil J. Wimmer, MD, MScy
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Cardiovasc Interv 2009;2:222–9.Letters to the EditorIs Ischemia Really Bad for You?We read with great interest the substudy of the Surgical Treatment
for Ischemic Heart Failure trial on inducible ischemia published
in the Journal alongside the accompanying editorial (1,2). This
fascinating report demonstrated that patients with inducible
myocardial ischemia and severe left ventricular systolic dysfunction
did not derive greater beneﬁt from coronary artery bypass grafting
compared with medical therapy. This fundamentally challenges
whether we should be revascularizing patients with left ventricular
systolic dysfunction on the basis of ischemia alone. Although
potentially practice changing, we believe that this is not necessarily
surprising, given that adverse events in patients with severe left
ventricular systolic dysfunction are more likely to relate to heart
failure rather than the underlying coronary atherosclerosis per se.
Indeed, this is also the likely explanation for the lack of beneﬁt
from statin therapy in this patient cohort (3,4).
The accompanying editorial goes on to ask the more wide
ranging question of whether ischemia is a legitimate target for
revascularization in any patient with coronary artery disease, irre-
spective of systolic function. We believe this is one of the most
fundamental questions facing cardiologists today. Early studies
established a clear association between increasing myocardial
ischemia and adverse events (5), leading to the assumption that
reducing ischemia, for instance with percutaneous coronary inter-
vention, would improve prognosis. However, percutaneous coro-
nary intervention has to date failed to demonstrate a consistent
reduction in myocardial infarction or mortality among patients with
stable disease, despite effectively reducing ischemia. Conversely,
statin therapy has profound effects on these outcomes, with rela-
tively little effect on the severity of coronary artery obstruction (6).
The question therefore arises whether ischemia is in itself bad for
you or whether it is in fact simply a surrogate for plaque burden.
Certainly plaque burden would better explain the results of the
